The FDA has approved Humira (Adalimumab) for the treatment of moderately to severly active ulcerative colitis (UC) in pediatric patients aged 5 years or older.
XELJANZ XR provides adult patients living with moderately to severely active UC the first and only once-daily JAK inhibitor for managing their disease.
The FDA issued a safety alert after results of a safety clinical trial showed increased risk of blood clots and death with higher dosages of the janus kinase inhibitor.
